News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Updates in the Management of Hairy Cell Leukemia

EP. 1: Introduction and Epidemiology of Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

EP. 2: Molecular Genetic Changes for Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

EP. 3: Signs and Tests for Diagnosis and Prognosis of HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

EP. 4: Differential Diagnosis and Molecular Tests in Identifying HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

EP. 5: Determining When to Treat and First-Line Therapy for HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

EP. 6: Combination First-line Therapy in Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

EP. 7: When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

EP. 8: Historical Treatment for Relapsed/Refractory HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

EP. 9: Landscape Change in the Treatment of Relapsed/Refractory HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

EP. 10: The Role of CD22-targeted Immunotoxins in HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

EP. 11: Treatments for Relapsed/Refractory HCL in Pipeline

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

EP. 12: Advice for Community Oncologists on Treating HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL